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Abstract
Deciphering the mechanisms regulating the generation of new neurons and new oligodendrocytes, the myelinating cells of
the central nervous system, is of paramount importance to address new strategies to replace endogenous damaged cells in
the adult brain and foster repair in neurodegenerative diseases. Upon brain injury, the extracellular concentrations of
nucleotides and cysteinyl-leukotrienes (cysLTs), two families of endogenous signaling molecules, are markedly increased at the
site of damage, suggesting that they may act as ‘‘danger signals’’ to alert responses to tissue damage and start repair. Here we
show that, in brain telencephalon, GPR17, a recently deorphanized receptor for both uracil nucleotides and cysLTs (e.g., UDP-
glucose and LTD4), is normally present on neurons and on a subset of parenchymal quiescent oligodendrocyte precursor cells.
We also show that induction of brain injury using an established focal ischemia model in the rodent induces profound
spatiotemporal-dependent changes of GPR17. In the lesioned area, we observed an early and transient up-regulation of GPR17
in neurons expressing the cellular stress marker heat shock protein 70. Magnetic Resonance Imaging in living mice showed
that the in vivo pharmacological or biotechnological knock down of GPR17 markedly prevents brain infarct evolution,
suggesting GPR17 as a mediator of neuronal death at this early ischemic stage. At later times after ischemia, GPR17 immuno-
labeling appeared on microglia/macrophages infiltrating the lesioned area to indicate that GPR17 may also acts as a player in
the remodeling of brain circuitries by microglia. At this later stage, parenchymal GPR17+ oligodendrocyte progenitors started
proliferating in the peri-injured area, suggesting initiation of remyelination. To confirm a specific role for GPR17 in
oligodendrocyte differentiation, the in vitro exposure of cortical pre-oligodendrocytes to the GPR17 endogenous ligands UDP-
glucose and LTD4 promoted the expression of myelin basic protein, confirming progression toward mature oligodendrocytes.
Thus, GPR17 may act as a ‘‘sensor’’ that is activated upon brain injury on several embryonically distinct cell types, and may play
a key role in both inducing neuronal death inside the ischemic core and in orchestrating the local remodeling/repair response.
Specifically, we suggest GPR17 as a novel target for therapeutic manipulation to foster repair of demyelinating wounds, the
types of lesions that also occur in patients with multiple sclerosis.
Citation: Lecca D, Trincavelli ML, Gelosa P, Sironi L, Ciana P, et al. (2008) The Recently Identified P2Y-Like Receptor GPR17 Is a Sensor of Brain Damage and a New
Target for Brain Repair. PLoS ONE 3(10): e3579. doi:10.1371/journal.pone.0003579
Editor: Kenji Hashimoto, Chiba University Center for Forensic Mental Health, Japan
Received June 6, 2008; Accepted October 8, 2008; Published October 31, 2008
Copyright:  2008 Lecca et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This project was supported by the Italian Ministry of Education, Progetti FIRB2003 #RBNE03YA3L_009 and COFIN-MIUR 2006059022 ‘‘PURINOCEPTORS
AND NEUROPROTECTION’’ to MPA, and by the CARIPLO Foundation Grant 2006/0882 ‘‘GENOMICS AND PROTEOMICS OF G PROTEIN-COUPLED RECEPTORS: NOVEL
TARGETS FOR THE DIAGNOSIS AND PREVENTION OF HUMAN DISEASES’’ to prof. Francesco Clementi, University of Milan, by the Progetto Alfieri, Fondazione CRT
to AB. GV has been supported by a fellowship by the Centro Neurolesi ‘‘Bonino-Pulejo’’, Messina, Italy.
Competing Interests: MLT, PC, CV, CM and MPA are inventors in the Italian Patent Application #2004A002007 on ‘‘Modulatori del recettore GPR17 e loro
impieghi terapeutici’’ submitted on October 21, 2004.
* E-mail: mariapia.abbracchio@unimi.it
. These authors contributed equally to this work.
Introduction
Extracellular adenine (ATP, ADP), uracil (UTP, UDP) and
sugar nucleotides (e.g., UDP-glucose and UDP-galactose) are
universal and phylogenetically ancient signaling molecules in-
volved in many biological processes, from embryogenesis to adult
homeostasis [1]. Their actions on target cells are mediated by
specific membrane receptors: the seven ligand-gated purinergic
P2X channels and the eight G protein-coupled P2Y receptors (the
P2Y1,2,4,6,11,12,13,14 receptors) [1,2]. Owing to their involvement in
the regulation of many physiological phenomena, dysfunctions of
nucleotides and their receptors have been associated to various
human diseases, including ischemic/inflammatory conditions
[1,2]. Instead, cysteinyl-leukotrienes (cysLTs, such as LTC4,
LTD4 and LTE4) are inflammatory 5-lipoxygenase arachidonic
acid mediators [3] with established roles in bronchial asthma [4]
acting through the G protein-coupled CysLT1 and CysLT2
receptors [5].
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Recent data highlight the existence of a functional crosstalk
between the nucleotide and the cysLT systems in orchestrating
inflammatory responses in various disease conditions, including
ischemic stroke. Both types of mediators accumulate at the sites of
inflammation, and inflammatory cells often co-express both P2Y
and CysLT receptors [6]. In rat microglia, the brain immune cells
involved in the response to cerebral hypoxia and trauma, the
activation of P2Y1 and CysLT receptors mediate co-release of
nucleotides and cysLTs [7], which might, in turn, contribute to
neuroinflammation and neurodegeneration. In the middle cere-
bral artery occlusion (MCAo) model in the rat, levels of cysLTs in
the lesioned cortex were sharply increased 4 h after MCAo and
rapidly declined afterwards [8]. In the same experimental model,
extracellular concentrations of ATP were instead constantly
elevated starting from 20 min after MCAo throughout a
220 min of microdialysis sampling, with a time course similar to
that of excitatory amino acids [9]. Thus, at the site of brain injury,
neurons and glia are exposed to high concentrations of both
extracellular nucleotides and cysLTs, suggesting that these
signaling molecules may act as ‘‘danger signals’’ to alert responses
to tissue damage and start repair.
We have recently reported that GPR17, a previously orphan G
protein-coupled receptor [10] (GPCR) at an intermediate
phylogenetic position between P2Y and CysLT receptor families,
is a new P2Y receptor specifically activated by both uracil
nucleotides (UDP, UDP-glucose and UDP-galactose) and cysLTs
(LTD4 and LTC4) [11]. Consistent with this hybrid pharmacology,
activation of GPR17 by uracil nucleotides was counteracted by the
P2Y receptor antagonists cangrelor and MRS2179, whereas its
activation by cysLTs was antagonized by montelukast and
pranlukast, two already marketed CysLT receptor blockers
(ibidem). Both the human and the previously unknown rat
receptor were found to be highly expressed in organs typically
undergoing ischemic damage, i.e., brain, heart and kidney.
Moreover, in the MCAo rat model, 48 hours after ischemia
induction, GPR17-immunoreactivity was markedly increased in
the ipsilateral cortex both within and at the borders of the ischemic
infarct, suggesting a potential role in the evolution of ischemic
damage. On the other hand, in a recent transcriptome study
comparing the gene expression pattern of human fetal and adult
neuroprogenitor cells (NPCs), GPR17 was identified as one of the
three genes that were exclusively expressed in adult hippocampal
NPCs [12], thus highlighting a potential role in brain repair. Thus,
GPR17 may have a differential role in brain response to injury,
depending upon whether the receptor is already constitutively
expressed by the cell or is induced as a result of brain insult.
Moreover, a differential role of GPR17 may also depend on
specific phases of brain response after the insult (sequentially,
death of irreversibly damaged cells, clearance of dead cells,
remodeling and repair).
On this basis, the present study has been specifically aimed at
assessing the localization of GPR17 in cells of different lineages
(neurons, glia and neural progenitor cells) of the intact mouse
brain and its changes at different times after induction of focal
cerebral ischemia in the MCAo model.
We show that in the intact brain GPR17 is expressed by neurons
and by a subset of adult quiescent parenchymal oligodendrocyte
progenitors. Following ischemia, GPR17 is sequentially induced in
neurons, microglia/macrophages and adult oligodendrocyte pre-
cursor cells, suggesting that it may act as a common regulatory gene
mediating response to injury in embryonically-distinct cell types.
This indicates GPR17 as a possible target for pharmacological
intervention in neurodegeneration processes including cerebral
ischemia and demyelinating diseases.
Results
Cloning and characterization of mouse GPR17
To study in detail the role of GPR17 in brain injury, the well
established model of focal cerebral ischemia in the mouse (MCAo)
was chosen. Thus, as a first step, we cloned and characterized the
previously uncharacterized murine GPR17 ortholog (GenBank
NM_001025381). Mouse GPR17, which is localized on chromo-
some 18, contains a 1020 base pairs open reading frame (ORF)
that encodes for a putative 339 amino acid protein 90 and 98%
identical to human and rat GPR17 [11]. Specific external primers
were used to amplify cDNA from several mouse tissues. Specific
PCR products of the expected mw (1022 bp) were obtained from
mouse brain, kidney, heart and skeletal muscle, but not from liver
and lung (Figure S1A). The 1022 bp PCR product from mouse
brain cDNA was then cloned into a pcDNA3.1/V5-His-TOPO
expression vector. The plasmid containing the positive murine
GPR17 clone (pcDNA3.1-Gpr17m) was used to transiently
transfect 1321N1 human astrocytoma cells, a cell line lacking
endogenous P2Y receptors and already utilized for the character-
ization of human and rat GPR17 [11]. Expression of the
transfected receptor was assessed by the appearance of a PCR
product of the expected 1022 bp length in cells receiving
pcDNA3.1-Gpr17m, whereas no expression of mGPR17 was
found in cells transfected with the corresponding empty vector
(Figure S1B). To confirm that the receptor transcript is indeed
translated into the receptor protein, we utilized a rabbit anti-
GPR17 polyclonal antibody that also recognizes human and rat
GPR17 [11]. As expected, upon incubation with this antibody,
1321N1 cells transfected with pcDNA3.1-Gpr17m showed a
specific immunoreactive signal which, instead, was not detected in
cells receiving the corresponding empty vector (Figure S1C). To
further confirm the specificity of these results, in the mGPR17-
expressing cells, pre-adsorption of the anti-receptor antibody with
the neutralizing peptide utilized for immunization completely
abolished the GPR17 signal (Figure S1C).
The pharmacological profile of mGPR17 was then assessed. Since
stimulation of GPCRs results in increased binding of GTP to G
proteins (which can, in turn, be quantified by measuring [35S]GTPcS
binding to purified membranes; see [13]), GPR17 activation in the
heterologous system was determined by testing the increase of
[35S]GTPcS binding by exogenously-added agonists in membranes
from transfected cells [13,14,15]. Full concentration-response curves
with the uracil nucleotide UDP, the sugar nucleotides UDP-glucose
and UDP-galactose and the cysLTs LTC4, LTD4 and LTE4 were
performed. In GPR17-expressing cells, UDP, UDP-glucose and
UDP-galactose concentration-dependently stimulated GTPcS bind-
ing with EC50 values of 5566.2, 8867.4 and 6867.3 nM,
respectively (Figure 1A). All tested leukotriene derivatives (i.e.,
LTC4, LTD4, and LTE4) were able to stimulate receptor-G protein
coupling with a similar potency, with estimated EC50 values of
0.7460.2 nM for LTC4, 0.6360.1 nM for LTD4 and
0.3160.09 nM for LTE4 (Figure 1B). None of these agonists, tested
at the highest concentration utilized in Figure 1A and 1B, had any
effect in cells transfected with the pcDNA3.1 empty vector
(Figure 1C). The ability of some known purinergic and cysLT
antagonists to counteract agonist-induced GTPcS binding stimula-
tion in cells expressing mGPR17 was also assessed. Cangrelor, a
P2Y12/13 antagonist, which displayed a high affinity towards human
and rat GPR17 [11] concentration-dependently inhibited GTPcS
binding stimulated by UDP with an IC50 value of 1.260.3 nM. In a
similar way, the CysLT1 antagonist montelukast concentration-
dependently inhibited GTPcS binding stimulated by LTD4, with an
IC50 value of 6164.6 nM (Figure 1D).
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Globally, these data characterize the previously unknown
mouse GPR17 receptor, demonstrate that this receptor is indeed
expressed at high levels in various organs (including brain) and
that, in a similar way to the already characterized human and rat
receptors, this receptor can be dually activated by two distinct
classes of endogenous ligands, uracil nucleotides and cysLTs,
which are both released in great amounts in the injured brain.
Moreover, they also show that the mouse receptor more closely
resembles the response profile of the human receptor [11].
In brain, GPR17 is normally expressed in neurons and in a
subset of adult neural precursor cells
We then utilized the specific anti-GPR17 antibody to determine
the cellular localization of GPR17 in control mouse brain. Coronal
sections taken at different brain levels were immuno-labeled with
the anti-receptor antibody in parallel with markers of neuronal or
glial cells. In the intact cerebral cortex, immunohistochemical
studies with a high sensitivity amplification kit revealed GPR17
expression in two distinct types of cells. One cell type had neuronal
morphology (see asterisks in Figure 2A): the neuronal nature of
these GPR17-positive (GPR17+) cells was confirmed by co-staining
with the neuronal specific markers SMI-311 (Figure 2B) and NeuN
(Figure 2C). Higher magnification analysis of these cells suggested
that, as expected for a GPCR, GPR17 was selectively expressed in
the plasma-membrane of NeuN+ neurons (Figure 2D, 2D9, 2D0).
Conversely, no co-localization was found with cortical astrocytes,
as shown by labeling with the specific markers GFAP (Figure 2E)
and S100b (Figure 2F). The other cell type expressing GPR17
displayed small cell bodies with fine radiating processes (see arrows
in Figure 2A, 2A9 inset, and arrows in Figure 2F). These cells were
dispersed in both gray (Figure 2A) and white matter (not shown)
and were reminiscent of precursor cells [16]. To investigate the
nature of the highly branched GPR17+ cells, we performed
staining for the pre-oligodendroglial specific proteoglycan NG2
[17]. Double-staining experiments revealed a heterogeneous
population of ramified cells. In particular, 3 distinct phenotypes
Figure 1. Effect of purinergic and leukotriene ligands on mGPR17 with [35S]GTPcS binding. Membrane aliquots (10 mg), obtained from
1321N1 cells transfected with pcDNA3.1-Gpr17m (A,B), were incubated with the indicated concentrations of purinergic (A) or leukotriene (B) agonists.
(C) Membranes from cells transfected with the pcDNA3.1 empty vector were incubated with UDP, UDP-glucose or UDP-galactose (all at 10 mM) or
with LTD4, LTC4 and LTE4 (all at 50 nM), as indicated. (D) Effect of P2Y or CysLT receptor antagonist on agonist-stimulated [
35S]GTPcS binding.
Membranes from pcDNA3.1-Gpr17m transfected cells were pre-incubated for 10 min with graded montelukast (1 nM-1 mM) or Cangrelor (0.01 nM-
100 nM) concentrations and then stimulated with 500 nM UDP or 50 nM LTD4, respectively. All data are expressed as percentage of basal [
35S]GTPcS
binding (set to 100%) and represent the mean6SEM of three different experiments each performed in duplicate.
doi:10.1371/journal.pone.0003579.g001
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of GPR17+ ramified cells were found: a first cell type was
characterized by exclusive expression of NG2 (arrowheads in
Figure 2G), a second by exclusive expression of GPR17 (white
arrows in Figure 2G) while a third cell type co-expressed both
markers (blue arrows in Figure 2G and inset). Quantitative analysis
of these cells showed that about 1/4 of the ramified GPR17+ cells
also displayed NG2 staining. Co-expression with markers of pre-
oligodendrocytes was further confirmed using an antibody against
the transcription factor Olig2, a key regulator of oligodendrocyte
development [17]. In this case, a much higher number of GPR17+
cells were also positive for Olig2. Quantitative fluorescence
microscopy analysis of full hemisphere sections in 3 animals
showed that 59.1865.46% of the ramified GPR17+ cells indeed
also co-expressed Olig2 in their nuclei (Figure 2H and 2H9; a
mean of 680652.2 GPR17+ cells were counted/animal; of these,
403649.7 also positively stained for Olig2).
Interestingly, in some Olig2 or NG2-labeled cells, GPR17
immunoreactivity displayed an asymmetrical subcellular localization,
suggesting GPR17 accumulation in the Golgi apparatus (Figure 2H0
and inset in Figure 2G). This specific staining pattern may represent a
well defined GPR17 maturation stage prior to distribution of the
receptor to the plasma-membrane. The branched GPR17+ cells did
not incorporate BrdU in their nuclei, at least under the conditions of
BrdU treatment utilized here (data not shown), suggesting that, in the
intact brain, GPR17 decorates a subset of quiescent non-proliferating
parenchymal oligodendrocyte precursors. Furthermore, no colocali-
zation of GPR17 was found with more mature myelinating
oligodendroglial markers, as shown by lack of double-staining with
Figure 2. Cellular localization of GPR17 in the intact mouse brain. Double fluorescence labeling of mouse brain coronal sections with anti-
GPR17 antibody (red fluorescence) and markers for different cell lineages (green fluorescence). (A) In the intact cortex, GPR17 expression is detected
in large round cells present at high density (examples are illustrated by asterisks) and in sparse ramified cells (arrows and A9 inset). Virtually all GPR17+
large cell bodies display co-expression of the neuronal proteins SMI311 (B) or NeuN (C), demonstrating their neuronal identity. D panels show higher
magnification images of two neurons showing immunopositivity for both GPR17 (red channel, D), and NeuN (green channel, D9); (D0) merge of the
two fluorescence channels. In cortex, we found no co-localization of GPR17 with the astroglial markers GFAP (E) and S100b (F, arrows indicate GPR17+
cells); several ramified GPR17-labeled cells instead co-stained for either NG2 (blue arrows in G) or Olig2 (H, H9), which are both pre-oligodendrocyte
markers. However, in the case of NG2, only a partial co-localization was found, since some cells only stained for NG2 (arrowheads in G) and some
others only stained for GPR17 (white arrows in G, H). Co-localization was much higher in the case of GPR17 and Olig2 (see text for quantification). In
some cases, NG2+ or Olig2+ cells show immunoreactivity for GPR17 in discrete cell body compartments (inset in G and H0, respectively; for details, see
text). I and J depict no co-localization of GPR17 with myelin-related proteins (CNPase in I and MAG in J). Some ‘‘resting’’ microglial cells were also
found in cortex, as suggested by staining with the specific marker Iba1 (K): in the intact brain, none of these cells expressed GPR17. Scale bars: A:
25 mm; A9, D, D9, D0, H9, H0: 10 mm; B, E, F, G: 50 mm; H, I, J, K: 20 mm.
doi:10.1371/journal.pone.0003579.g002
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either CNPase (Figure 2I), myelin-associated glycoprotein MAG
(Figure 2J) and myelin basic protein MBP or APC (data not shown),
suggesting that GPR17 may be expressed at a specific stage of
oligodendroglial differentiation. Finally, no GPR17 co-expression
was found in resting microglia detected by anti-Iba1 staining in the
intact brain (Figure 2K) (however, see: ‘‘Expression pattern of GPR17
during ischemia evolution’’).
GPR17+ ramified cells were also found in corpus callosum: most
of these cells co-stained for Olig2 but not with NG2 and did not
seem to proliferate under resting conditions (not shown).
Interestingly, in c. striatum, GPR17+ precursor cells were not
positive for MBP, but were often found physically associated to or
inside myelinating fibers (Figure S2).
Based on previous data demonstrating that GPR17 is one of the
3 key genes expressed in human adult NPCs [12], we also looked at
the presence of GPR17+ cells in classical mouse brain neurogenic
areas, i.e., the subventricular zone (SVZ) of lateral ventricles (LV)
and the dentate gyrus (DG) of hippocampus. The first layer of
brain ventricles wall consists of ependymal cells, i.e., radial glia-
derived cells that intensively stain for the astrocyte marker S100b
[18] (green fluorescence in Figure 3A). Several of these cells were
also immunoreactive for GPR17 (red fluorescence in Figure 3A;
cells expressing both S100b and GPR17 are in yellow). GPR17+
ramified cells with a morphology very similar to that of the
parenchymal precursors described above were also detected
immediately below the ependyma as well as in more profound
layers of the subependymal zone (Figure 3B–D). These cells never
co-stained with either the stem cell marker nestin (not shown),
GFAP (Figure 3B) or the neuronal precursor marker double-cortin
(DCX) (Figure 3D), suggesting that GPR17 is not expressed by
GFAP+ multipotent stem cells or by DCX+ neuronal precursors
[19,20,21]. Highly branched GPR17+ cells were also found in the
subgranular layer of the hippocampus (Figure 3E); also here, no
colocalization of GPR17 with the adult neural stem cell marker
GFAP was found. None of these GPR17+ precursors proliferated
under normal conditions.
Globally, the data described above show that, in the intact
mouse brain, GPR17 is expressed by neurons and by a subset of
precursor cells in both parenchyma and neurogenic areas. In the
parenchyma, GPR17 segregates to a subset of NG2+/Olig2+
precursor cells that never proliferated under control conditions,
suggesting that there are quiescent pre-oligodendrocytes. In the
neurogenic areas, GPR17 decorates a subset of non-proliferating,
nestin2, GFAP2 and DCX2 cells of yet undefined nature.
Figure 3. GPR17 expression in the mouse germinative zones. Micrographs depicting GPR17 staining in coronal sections of the intact anterior
forebrain. (A) In the walls of the lateral ventricles (LV), GPR17 (red fluorescence) is highly expressed in ependymal cells, which are in direct contact
with ventricle cavities and also express the S100b protein (green fluorescence). Cells co-expressing both GPR17 and S100b in this cell layer are
indicated in yellow. (B, C) Specific GPR17 staining (red fluorescence) is also found in the subependymal layer of LV. (B): several of these cells show a
morphology that is reminiscent of the GPR17+ oligodendrocyte precursors found in brain parenchyma (see also Figure 2 and panel D). These GPR17+
cells do not co-stain for the astrocytic marker GFAP (green fluorescence in B), that is also specifically expressed by multipotent adult stem cells. (C) As
expected, in the subependymal layer of lateral ventricles, several double-cortin (DCX)+ neuronal precursors are evident (red fluorescence); however,
these cells do not co-express GPR17 (here shown in green fluorescence). (D) An additional image of GPR17+ ramified precursors (red fluorescence) in
LV subependymal layer (arrows) and in c. striatum (CST) of brain parenchyma (Hoechst 33258 staining of cell nuclei is also shown in blue). GPR17+
cells in the subependymal layer were often found to protrude their processes in the ventricular cavity. (E) Double fluorescence image showing
expression of GPR17 (red fluorescence) in ramified cells in the hippocampus (DG: dentate gyrus). Also in this brain area, GPR17 immunoreactivity does
not co-localize with GFAP (green fluorescence). Scale bars: A–C 50 mm; D 10 mm; E 100 mm.
doi:10.1371/journal.pone.0003579.g003
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Activation of GPR17 in vitro by the endogenous agonists
UDP-glucose and LTD4 promotes pre-oligodendrocyte
differentiation to mature myelinating cells
To gain more information on the role of GPR17 in pre-
oligodendrocyte precursors, we characterized the behaviour of
these cells in mixed neuron/glia cortical cultures, where many
GPR17+ cells were found (Figure 4A–H). These cells displayed a
very typical highly ramified morphology resembling that of the
precursor cells found in vivo. As also observed in the intact brain for
the parenchymal precursors, these GPR17+ cells never expressed
nestin (Figure 4A), GFAP (Figure 4B), MAP2 (Figure 4C) or b–
TubIII (Figure 4D), suggesting that they are not stem cells, nor
astrocytes or neurons. To investigate in detail whether GPR17 is
specifically expressed by pre-oligodendrocytes, we performed
double staining experiments with a set of markers identifying
different stages of differentiation, i.e., NG2 (oligodendrocyte
precursor), O4 and CNPase (pre-oligodendrocytes, immature/
mature cells), and MBP (mature oligodendrocytes) [22,23].
GPR17+ cells were found to co-express either NG2 (arrows in
Figure 4E), Olig2 (not shown), O4 (arrows in Figure 4F), or, to a
lesser extent, CNPase (Figure 4G), confirming that they are indeed
oligodendrocyte precursors. Conversely, very few cells co-
expressed the mature oligodendrocyte marker MBP (Figure 4H;
see also below). Expression of GPR17 in oligodendrocyte
precursors was also confirmed by single-cell PCR. For this
analysis, one cell or a small group of cells (up to 10) were picked
up from living cultures using cell morphology as a guide at the
light microscope (see arrows in Figure 4I). Receptor expression
was detected in both the single-cell and the 10-cell samples, as
indicated in the PCR panel of Figure 4I, where rat cortex was
utilized as a positive control.
The number of the GPR17+ precursors constantly increased
with time in culture (Figure 4J). A quantification of the percentage
of the GPR17+ cells at various oligodendrocyte differentiation
stages in 10-day old cultures is shown in Figure 4K. A prevalence
of GPR17+ cells expressing early oligodendroglial markers such as
NG2 or O4, was constantly found. No significant relative changes
of this distribution was observed with time in culture, at least up to
day 20 (data not shown).
In order to verify whether GPR17 in cultured precursors is
functional and whether its activation can promote cell progression
along their differentiation pathway, cultures were treated with
UDP-glucose, which selectively binds to this receptor and activates
it [11]. Exposure of cultures to a maximal concentration (100 mM)
of UDP-glucose for 72 h did not have any effect on cell viability, as
demonstrated with propidium iodide (PI) that does not enter viable
intact cells and can only label the nuclei of cells with damaged
permeabilized membrane. In control cultures, PI labeled a small
percentage of cells (16.363.5%, n= 4). This low percentage of cell
death, which is reasonably expected for a primary in vitro culture,
was not different in UDP-glucose treated cells (13.761.9%, n= 4).
UDP-glucose treatment instead resulted in a significant increase of
the number of GPR17+ precursor cells, suggesting that activation
of the receptor may itself promote receptor expression, and, more
important, it markedly increased the number of mature MBP+
oligodendroglial cells (Figure 4L). Both effects were partially
counteracted by the P2Y receptor antagonist cangrelor (ibidem).
Exposure to a maximal concentration (100 nM) of LTD4 also
significantly increased both the number of GPR17+ and mature
MBP+ oligodendroglial cells (Figure 4M). No synergistic effects
were observed when cells were treated with a combined protocol
(Figure 4M). The total number of cells in culture did not
significantly increase during the 72 h treatment period with
pharmacological agents, as suggested by labeling of cell nuclei with
Hoechst 33258 (Figure 4L and 4M), to support the conclusion
that, in these cultures, activation of GPR17 by its endogenous
agonists is actually inducing the in vitro maturation of already
existing oligodendrocyte precursors.
Thus, GPR17 is already functional in pre-oligodendrocytes and
its activation promotes the progression of these cells along their
differentiation pathway.
Expression pattern of GPR17 during ischemia evolution
To characterize the changes of GPR17 occurring during
ischemic damage, mouse brains were processed for immunohis-
tochemistry at 24, 48, 72 hours and 1 week after MCAo. Within
the lesioned area, a strong up-regulation of GPR17 was observed
24 h after MCAo (Figure 5A) with respect to the corresponding
unlesioned area of the contralateral cortex (Figure 5C). Inside the
injured area, most of the GPR17+ cells co-localized with the
neuronal marker NeuN (Figure 5B), suggesting that receptor up-
regulation indeed occurred in neurons. Forty-eight hours after
MCAo, a dramatic decrease of both the number of neuronal cells
and of GPR17 immunoreactivity was found inside the lesion,
suggesting that neurons over-expressing GPR17 at 24 h had
undergone cell death (Figure 5D). Several shrunk cells overex-
pressing GPR17 and resembling damaged neurons were also
found at the borders of the ischemic infarct (Figure 5D). Some of
these cells also positively stained for NeuN (data not shown) and
for the chaperon protein HSP70 (Figure 5E), which is known to be
up-regulated in neurons upon damage [24]. Western blot analysis
of GPR17 performed in membrane (M) and cytosolic (C) fractions
confirmed increased expression of a membrane protein band of
approximately 50 kDa (likely corresponding to a glycosylated form
of the receptor) in the lesioned hemisphere (MCAo) compared to
the intact contralateral (Con) side (Figure 5, right panel). As
expected for a membrane receptor, no specific signal for the anti-
GPR17 antibody was detected in cytosolic fractions (ibidem). To
confirm that this band is indeed GPR17, immunolabeling was
abolished in the presence of the neutralizing peptide. A
quantification of the MCAo-induced up-regulation of GPR17 is
shown in histograms. Globally, these findings suggest that, upon
damage, GPR17 is up-regulated in injured neurons and that this
up-regulation may be causally related to cell death. At this stage of
damage development, GFAP+ activated astrocytes indicating
astrogliosis were also visible at the borders of the injured area,
but none of these cells expressed GPR17 (data not shown).
Starting from 48 h and highly evident seventy-two h after
MCAo, a marked expression of GPR17 was found at the
boundaries of the lesioned area (Figure 5F), but this time
immunoreactivity was associated to cells also expressing IB4, a
marker of activated microglia/macrophages (Figure 5G). Under
the staining conditions utilized here, no specific IB4 labeling was
detected in the intact contralateral side (data not shown). One
week after MCAo, GPR17 immunopositivity was again increased
within the damaged area: also these cells were all IB4+, suggesting
that they are indeed the macrophages/microglia found at the
lesion borders at day 3, that were now infiltrating the lesioned area
(data not shown). These data show that after up-regulation in
neurons, there is a second wave of GPR17 induction in microglia/
macrophages as soon as these cells are activated and recruited
toward the lesioned area as a consequence of damage.
Based on the demonstration of GPR17 on NPCs [12] (Figure 3)
and on the finding that ischemic damage induces proliferation of
adult NPCs in brain’s neurogenic areas and parenchyma [25], we
investigated whether cells expressing GPR17 also underwent
proliferation after MCAo, as assessed in vivo by BrdU administra-
tion. As shown in Figure 6, 72 h after MCAo, a marked increase in
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Figure 4. Presence and activation of GPR17 in oligodendrocyte precursor cells of primary cortical cultures maintained in vitro.
Several GPR17+ ramified cells (green fluorescence) reminiscent of the precursors found in vivo were consistently found in primary neuron/glia cortical
cultures. Micrographs (A–H) show their phenotype characterization. These cells (green fluorescence) did not co-express the stem cell marker nestin
(A), or the astrocytic marker GFAP (B), or the neuronal markers MAP2 (C) and b-TubIII (D), but were instead positive for several pre-oligodendrocyte
markers, such as NG2 (arrows in E) and O4 (arrows in F), which appear quite early during oligodendrocyte differentiation. Colocalization of GPR17 with
these markers is shown in yellow-orange cells. A lower number of GPR17+ cells also expressed CNPase (arrow in G) and very few costained for MBP
(arrow in H), which are markers of more mature oligodendroglia (for more details, see text). In blue, Hoechst 33258 stained nuclei. Single cell RT-PCR
was used to confirm expression of GPR17 in oligodendroglial-like cells (I). For this analysis, cells were picked up from living cultures using cell
morphology as a guide at the light microscope. Left micrograph: an example of a brightfield showing cells (arrows) with oligodendrocyte
morphology. These cells can be distinguished from neurons based on their size (approximately 1/3 the size of neurons), phase-dark cell bodies and
presence of fine ramifications. The oligodendrocyte nature of cells with this morphology was confirmed by co-immunostaining for O4 and GPR17 at a
subsequent time after culture fixing (arrows in right micrograph). By following this method, one living cell or a small number of cells (up to 10) were
sucked from living cultures (see MATERIALS AND METHODS) and processed for RT-PCR analysis. Significant GPR17 expression was detected in both
the single-cell and the 10-cell samples, as indicated in the PCR panel. Rat cortex was utilized as a positive control (see last lane). Scale bars: 15 mm. In
these primary cultures, the number of GPR17+ cells spontaneously increased as a function of time (J); DIV: days in vitro. (K) Quantification of the
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the number of proliferating cells was found in the lesioned
ipsilateral hemisphere with respect to the corresponding unle-
sioned side (compare green dots in brain’s schematic drawing).
Two main types of BrdU+/GPR17+ cells were found in the
ischemic side. The first cells were mainly found at the borders of
the injured area (indicated as 1 in brain’s drawing) and appeared
Figure 5. Time course of GPR17 expression after MCAo in mice. Micrographs show coronal brain slices obtained from mice 24, 48, 72 hours
after MCAo. Brain drawings in insets show the areas (squares) where micrographs were taken. (A) Twenty-four h after MCAo, immunohistochemistry
with an anti-GPR17 antibody (red fluorescence) show a marked up-regulation of the receptor within the ischemic lesioned area (the region delimited
by the dotted line). Basal expression of GPR17 in the corresponding contralateral area is shown in C for comparison. (B) Cells showing marked GPR17
expression inside the lesioned area also express the specific neuronal marker NeuN, confirming that these cells are indeed neurons. (D) Forty-eight h
after MCAo, GPR17+ neurons inside the lesioned area are markedly reduced, suggesting induction of cell death. At this time point, a marked up-
regulation of GPR17 appears in neurons at the border of the lesion. (E) These cells co-localize with the neuronal damage marker HSP70 (see text for
more details). Up-regulation of GPR17 in the ischemic area is also confirmed by western blot analysis in membrane (M) and cytosolic (C) fractions from
intact contralateral (Con) and ipsilateral ischemic (MCAo) cortex of mice (right panel). GPR17 is identified with an anti-GPR17 antibody as an
immunoreactive protein band with an approximate 50 kDa molecular weight; as expected for a membrane receptor, this band is present in
membranes but not in cytosolic fractions. To confirm blot specificity, the 50 kDa protein band is abolished in the presence of the neutralizing peptide
(indicated as+pept). A marked increase of the intensity of this band is found after MCAo (the quantification of this increase is shown in histograms as
% of control set to 100%; results from 5 experiments). Forty-eight h (not shown) and seventy-two h after MCAo (F), there is a marked increase of
GPR17+ cells at the border of the lesioned area. (G) These cells are not neurons but they are microglia/macrophages infiltrating the ischemic area,
since most of them also positively stain for IB4, a microglia/macrophage marker (see also text). These GPR17+/IB4+ cells are indeed found inside the
lesioned area one week after MCAo (data not shown). Scale bars: 50 mm.
doi:10.1371/journal.pone.0003579.g005
percentage of GPR17+ cells that also co-express the indicated oligodendrocyte markers. Total number (n) of GPR17+ cells counted from two different
coverslips for each preparation: for NG2, n = 3502; for O4, n = 2685; for CNPase, n = 1738; for MBP, n = 3615. Data were obtained from five different
primary culture preparations. (L) Exposure of cultures to maximal (100 mM) UDP-glucose (UDP-glc) concentrations for 72 h induced a highly
significant increase in the number of mature MBP+ oligodendroglial cells. The number of GPR17+ cells was also increased. Both effects were partially
counteracted in the presence of the P2Y receptor antagonist cangrelor. (M) Exposure of cultures to maximal (100 nM) LTD4 concentrations for 72 h
also induced a significant increase in the number of mature MBP+ oligodendroglial cells and of GPR17+ cells. No synergistic nor additive effects were
found when both agonists were combined together. There were no significant changes in the total number of cells in culture during the 72 h
treatment, as shown by labeling of cells nuclei with Hoechst 33258. *p,0.05 compared to control; ** p,0.05 with respect to UDP-glc and not
different from control; # p=0.15 with respect to control and P= 0.245 with respect to UDP-glc, one-way analysis of variance (ANOVA).
doi:10.1371/journal.pone.0003579.g004
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as small globular cells (Figure 6A) which markedly stained for IB4
(Figure 6B). So, these cells are the microglia/macrophages about
to infiltrate the lesioned tissue, already shown in Figure 5. The
morphology of the second proliferating cell type very closely
resembled the parenchymal highly branched pre-oligodendrocytes
already described in Figure 2 (see also Figure 6C) and positively
stained for both GPR17 (Figure 5D) and Olig2 (Figure 5E). These
parenchymal branched GPR17+ precursors were consistently
Figure 6. Characterization of proliferating cells in adult mouse brain after induction of MCAo. To evaluate injury-induced cell
proliferation, BrdU (50 mg/Kg) was administered twice a day for 3 days to ischemic mice starting from the afternoon of MCAo. Animals were sacrified
4 h after the last BrdU injection and coronal brain slices prepared for immunohistochemical analysis (for further details, see Materials and Methods).
Seventy-two h after MCAo, a marked increase of BrdU+ cells is found in the ipsilateral lesioned hemisphere with respect to the contralateral
unlesioned side (compare green dots in brain’s drawing). Many of these cells are also GPR17+. Two main types of BrdU+/GPR17+ cells are found. (A, B)
A first, small globular cell type is mainly found in the peri-lesioned area (indicated as 1 in brain’s drawing); these cells also markedly stain for IB4 and
are indeed the microglia/macrophages about to infiltrate the ischemic lesion already described in Figure 5. (C–E) A second, ramified BrdU+/GPR17+
cell type (D) reminiscent of the parenchymal Olig2+ pre-oligodendrocytes (C, E; see also text) already described in the intact brain (Figure 2) is
consistently found in the c. striatum (indicated as 2 in brain drawing) as well as in regions closer to the lesioned area (not shown). The number of
these cells was significantly higher in the ipsilateral with respect to the unlesioned contralateral side (see text for more details). (F, G) Some of these
proliferating precursor cells also positively stained for APC, a marker of mature oligodendroglia, suggesting initiation of re-myelination. (H) As
expected, in the ispilateral SVZ (indicated as 3 in brain drawing), a marked increase of double-positive BrdU+/DCX+ cells is found with respect to the
unlesioned hemisphere. However, none of these cells expressed GPR17 (not shown). Scale bars: 50 mm.
doi:10.1371/journal.pone.0003579.g006
Targeting GPR17 in Neurorepair
PLoS ONE | www.plosone.org 9 October 2008 | Volume 3 | Issue 10 | e3579
found in the c. striatum (indicated as 2 in brain drawing) as well as
in regions closer to the lesion borders. Quantification of the
GPR17+ precursor cells in 3 animals revealed a 24.0765.23%
increase in number with respect to the unlesioned contralateral
side (total number of cells counted: 2542 and 2039 in the ischemic
versus the contralateral side). At variance from the intact brain, in
the injured brain, some of these precursor cells also positively
stained for APC, a marker of mature oligodendroglia (Figure 6F
and 6G). As expected, brain injury also induced the activation of
precursor cells in the SVZ (indicated as 3 in brain drawing), where
many BrdU+/DCX+ cells started proliferating (Figure 6H).
However, no changes in GPR17+ cells were found in this
neurogenic area (not shown) at least at this time frame after
MCAo.
Globally, these data show that induction of brain damage is
associated to activation of GPR17. Very early (24 h) after the
insult, GPR17 is transiently upregulated in neurons (which already
express this receptor under physiological conditions) in parallel
with the appearance of the cellular stress marker HSP70. GPR17
labeling in the lesioned area decreases as cell death progresses.
Starting from 48–72 h after ischemia, GPR17 immuno-labeling
appears on microglia/macrophages infiltrating the injured area.
At this stage, a subset of GPR17+ oligodendrocyte progenitors in
the peri-lesion area start to proliferate and to express mature
oligodendroglia markers, suggesting differentiation to mature cells.
The in vivo knock down of GPR17 markedly attenuates
brain ischemic damage in mice
The data shown above suggest that GPR17 may represent a
‘‘sensor’’ of damage activated very early during ischemia induction
and contributing to cell death. If this were true, its inhibition
during MCAo should contrast cell death inside the ischemic core
and attenuate the evolution of ischemic damage. To address this
issue, 6 mice received an anti-sense oligonucleotide (616)
specifically designed to knock down this receptor in vivo. Animals
were injected intracerebroventricularly 20 min and 24 h after
MCAo. This biotechnological strategy [26] has been proven to
very efficiently downregulate other GPCRs in the brain [27,28]
and has been already successfully utilized by us in ischemic rats
[11]. Another group of 6 animals received in parallel a
‘‘scrambled’’ oligonucleotide randomly generated on the basis of
the nucleotide sequence of 616. This group of animals was utilized
as a control group in this set of experiments. Finally, another
group of 6 animals received Cangrelor, that, although not selective
for GPR17 (see ‘‘Cloning and characterization of mouse
GPR17’’), has been shown by us to potently inhibit GPR17 in
both the rat [11] and in the mouse (the present study). The
evolution of ischemic damage was followed longitudinally in living
animals by Magnetic Resonance Imaging (MRI) at 2, 24 and 48 h
after MCAo. There were no changes between groups in the mean
brain ischemic volume at 2 h after MCAo (see Figure 7 legend). In
the lesioned hemispheres of animals receiving the scrambled
oligonucleotide, as expected, brain infarct volume increased
dramatically between 2 and 48 h. Conversely, in animals treated
with 616, progression of ischemic damage at 24 and 48 h was
markedly reduced, and, in the case of Cangrelor, totally abolished
(see Figure 7A for representative images and Figure 7B for
quantification and statistical analysis).
Bioinformatic analysis showed that 616, that effectively reduced
brain infarct evolution, was not homologous to any other GPCR
(see MATERIALS AND METHODS). This strongly indicates
that GPR17 is indeed the specific target of 616, thus confirming a
specific role for this receptor in the changes associated to ischemic
damage development.
Discussion
GPR17: a receptor with a dual role in both neuronal
death and in brain repair?
We have previously suggested that an up-regulation of the
hybrid nucleotide/cysteinyl-leukotriene receptor GPR17 in the
ischemic brain may contribute to the evolution of damage [11]. A
causal link between up-regulation of GPR17 and extent of brain
damage was suggested by data showing that inhibition of GPR17
by either pharmacological agents or by an antisense-oligonucle-
otide strategy markedly attenuated cell death (ibidem). However,
GPR17 has also been reported to be one of the 3 key genes
expressed in human adult neuroprogenitor cells [12], which would
Figure 7. Effect of the in vivo knock down of GPR17, by either a biotechnological or a pharmacological strategy, on brain infarct size
evolution, as determined by MRI. (A) Representative Tr(D) images of coronal brain sections from ischemic mice treated with either an anti-sense
oligonucleotide specifically designed to knock down GPR17 (616) or Cangrelor (Can), in comparison with animals treated with a ‘‘scrambled’’
randomly designed oligonucleotide (Scr). Images were taken from the same animals at 2, 24 and 48 h after MCAo. Dotted lines indicate the extension
of the ischemic infarct. (B) Quantitative analysis of infarct size volume at 24 and 48 hours after MCAo in mice receiving Scr, 616 or Can (mean of 6
animals/group). Data are expressed as percentage variation of infarct volume at 24 and 48 h after MCAo compared to 2 h considered as 100% (see
also MATERIALS AND METHODS). There were no statistically significant differences between groups in the ischemic infarct volumes at 2 h
(Src = 23.467.47; 616 = 23.967.2; Can= 16.464.23 mm3). **P,0.001 versus 2 h; # P,0.05 versus corresponding Scr animals.
doi:10.1371/journal.pone.0003579.g007
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instead suggest a potential role in brain repair. These apparently
conflicting results suggest that GPR17 might play differential roles
in different cell types and/or under specific pathophysiological
conditions; for example, it may well be that, upon injury, GPR17
is induced in distinct cell types depending upon specific phases of
damage development, remodeling and repair.
On this basis, the present study was purposely undertaken to (i)
define the cellular localization of GPR17 in the intact mouse brain
and shed light on its potential roles under physiological conditions;
and (ii), to define possible changes of this receptor in the cell types
that participate to brain damage and repair in a well-established
focal ischemia model such as the MCAo model in the mouse.
Mouse GPR17 closely reproduces the functional features
of human GPR17
As a first step to these aims, we cloned and characterized the
previously unknown mouse ortholog of GPR17 and compared its
pharmacology with that of the already known human receptor [11].
Mouse GPR17 is 90% identical to the human receptor and,
importantly, its response profile to ligands is closer to that of the
human receptor with respect to the rat receptor. Despite some
differences in the affinities of UDP and UDP-glucose, which were
more potent at the mouse compared to the human receptor,
potencies of cysLTs were in the same range. Moreover, while the
endogenous ligand UDP-galactose is totally ineffective at rat GPR17,
this nucleotide significantly activates both the human [11] and the
mouse receptor (the present study). Finally, for antagonists, while
there are significant differences between man and rat, the P2Y and
CysLT blockers cangrelor and montelukast display almost identical
antagonistic activities at both human and mouse GPR17 ([11];
Figure 1). Therefore, globally, the mouse receptor more closely
reproduces the features of the human receptor, thus validating the
mouse MCAo model utilized here as the most appropriate
experimental model to assess the role of GPR17 in brain injury.
GPR17 as a new player in oligodendrocyte differentiation
Immunohistochemical studies with a specific, in-house made anti-
GPR17 antibody showed that, in the intact mouse telencephalon,
GPR17 is present on both neurons and in a subpopulation of ramified
non proliferating Olig2+ or NG2+ precursor cells dispersed in both
gray and white matter. In particular, the number of ramified
precursors expressing both Olig2 and GPR17 is very high, to suggest
that Olig2, which is a transcriptional factor, may drive the expression
of GPR17 in these cells. By bioinformatic analysis, we indeed found
14 potential Olig2-responsive elements in the upstream region of the
GPR17 gene. These responsive elements can bind to either Olig2
itself or to other members of the Olig2 transcription factor family,
such as Atoh1, Neurod1, Neurod2, Neurod4, Neurod6, Neurog1,
Neurog2, Neurog3, TGF12 and TGF3 (Figure S3). In both the
human, rat and mouse GPR17 upstream regions, 6 phylogenetically
conserved domains were found: two of them (indicated as E-Box 1
and E-Box 2 in Figure S3) are particularly interesting, since they are
identical in the 3 species and contain 2 responsive elements for
members of the Olig2 transcription factor family.
In the intact brain parenchyma, none of the GPR17+ precursor
cells expressed either GFAP, or DCX or mature oligodendrocyte/
myelination markers, suggesting that GPR17 specifically decorates
mature neurons and quiescent pre-oligodendrocytes. Interestingly,
in c. striatum, immature GPR17+/MBP-negative precursor cells
were often found physically associated to or inside myelin tracts,
which have been previously shown to also contain immature
Olig2+ cells [29]. These GPR17+ cells may represent a source of
pre-oligodendrocytes able to turn into myelinating cells when
necessary; alternatively, these cells could play a role in the local
trophic control of myelination. To confirm the link between
GPR17 and the oligodendroglial lineage, highly ramified GPR17+
precursors specifically expressing markers identifying different
stages of oligodendrocyte differentiation are also present in
primary cultures obtained from cortical parenchyma. In a similar
way to what observed in vivo, under control conditions, these cells
are not positive for either stem cell, neuronal or glial markers, and
very few of them express MBP, a marker of mature oligoden-
droglia. This suggests that GPR17 expression is specifically
segregated to the early stages of the oligodendrocyte differentiating
pathway, and that the receptor is turned down when these cells
reach functional maturation (in this respect, see also below).
In vivo, GPR17 is also present in both cells of the ependymal layer
and in a subset of subependymal precursor cells of the lateral
ventricles, one of the classical neurogenic areas that are still active in
the adult brain. Again, none of these cells express either GFAP,
nestin or DCX, suggesting that they are not ‘‘classical’’ multipotent
neurogenic cells or neuronal precursors; moreover, in a similar way
to the parenchymal GPR17+ precursor cells, they did not
incorporate BrdU (at least under the experimental conditions
utilized here). These cells may thus represent an additional yet-
uncharacterized population of quiescent (or very slowly proliferat-
ing) precursors, or may be postmitotic SVZ-derived progenitors
progressing along the oligodendroglial differentiation pathway. A
similar population of ramified GPR17+ cells was also found in the
hippocampus, another neurogenic area present in the adult brain.
To verify if GPR17 in oligodendrocytes precursors is indeed
functional and could play a role in driving differentiation to mature
myelinating cells, primary cortical cultures were treated in vitro with
UDP-glucose, one of the endogenous agonists of GPR17 [11].
Exposure to this agonist for 72 h resulted in an approximately 3-fold
increase of the number of mature MBP+ cells. To confirm the
specificity of these effects, we demonstrated that the P2Y receptor
antagonist cangrelor (that was previously demonstrated to contrast
GPR17 activation both in vitro and in vivo [11], the present study),
partially counteracted UDP-glucose induced changes. LTD4, which
also acts as an agonist at GPR17 ([11]; the present study), induced
similar effects, suggesting that activation of GPR17 on oligoden-
drocyte precursors by its endogenous agonists promotes progression
along their differentiation pathway. In treated cultures, the total
number of cells was not increased, to suggest that activation of
GPR17 is actually inducing the maturation of already existing
precursors. No synergistic nor additive effects were noticed when
both agonists were combined together. However, since maximal
concentrations of both UDP-glucose and LTD4 were used in this
study, the plateau response may have been already achieved with
the single agonist concentration, or the receptor may have
undergone agonist-induced desensitization, a typical feature of
GPCRs [30]. Future studies employing combinations of different
agonist concentrations will clarify this aspect.
In line with these in vitro findings, application of a brain injury in
vivo, such as induction of focal cerebral ischemia, promotes the
activation of quiescent GPR17+ oligodendrocyte precursors that
start proliferating in the parenchyma around the injured area. In
the lesioned brain, some of these cells also start expressing more
mature myelination markers such as APC, that are never
expressed by quiescent GPR17+ precursors in the intact
telencephalon (see also below).
Upon brain ischemia, GPR17 is induced in several
embryonically different cells that participate to damage
evolution and repair
We finally looked at the expression pattern of GPR17 in mice
after induction of MCAo. We provide evidence that:
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(i) Upon ischemia induction, there is an early, time-dependent
up-regulation of GPR17 in neuronal cells both within and at
the borders of the injured area. Numerous neurons over-
expressing GPR17 are already evident inside the lesioned
area 24 hours after MCAo. Several of these neurons co-
localize with inducible HSP70, a marker of cellular stress,
injury and death, suggesting a causal link between GPR17
up-regulation and neuronal death. To confirm this potential
link, at 48 hours, GPR17+ neurons are no longer present
inside the lesion suggesting that they have indeed undergone
death. To further confirm a causative role of the receptor in
induction of cell death inside the ischemic core, the in vivo
knock down of GPR17 by either a pharmacological or a
biotechnological approach markedly reduced the ischemic
infarct volume (Figure 7).
(ii) Starting from 48–72 hours after MCAo, at the borders of the
lesioned area, we found many GPR17+ cells that also
strongly stained for IB4, a marker of activated microglia/
macrophages. As expected, no IB4+ cells are found in the
intact cortex, where all microglia was present in its ‘‘resting’’
form (Figure 2K). One week after MCAo, these cells are
detected in high amount inside the ischemic lesion (data not
shown). This pattern of IB4 positivity indeed reproduces the
typical distribution of infiltrating cells in the ischemic brain
[31]. It is not possible to establish whether these infiltrating
cells are microglia or blood-borne macrophages or both,
since under these experimental conditions both types of cells
are positive to the same surface and endocellular markers
(such as IB4). GPR17 immunoreactivity in these cells is not
due to phagocytosis of GPR17 over-expressing neurons by
microglia/macrophages, since none of these cells expresses
typical neuronal markers such as SNAP25 [32].
(iii) Starting from 72 hours after MCAo, the number of ramified
GPR17+ oligodendrocyte precursor cells is also significantly
increased both around the injured area and in the corpus
striatum. These data are in line with previous literature data
demonstrating that, in a similar way to neurons, oligoden-
drocytes are very vulnerable to brain damage in vivo and
proliferation of oligodendrocyte precursor cells is detected
after ischemia around the lesioned area [33], likely as a
response to demyelination. Activation of oligodendrocyte
precursor cells may contribute to the replenishment of
oligodendrocytes and subsequent remyelination in the peri-
injury area. In line with this hypothesis, at variance from the
intact telencephalon, in ischemic animals, some of the
GPR17+ parenchymal precursors also expressed typical
mature oligodendroglia markers such as MBP (data not
shown) and APC, to suggest that, upon damage, quiescent
precursors are activated and start progressing along their
differentiation pathway. Of course, in future experiments, it
will be interesting to verify if, at later times after ischemia,
these activated pre-oligodendrocytes start myelinating, thus
actually supporting repair of demyelinated lesions.
(iv) In line with previous data demonstrating that ischemic
insults activate precursor cells in classic neurogenic areas
[25], many BrdU+/DCX+ cells were found in the SVZ of
lesioned mice. However, none of these proliferating cells
expresses GPR17, indicating a differential behaviour/
regulation of GPR17+ precursors in brain parenchyma and
in adult neurogenic areas. Based on the demonstration that
GPR17 is specifically activated by uracil nucleotides and
cysLTs (e.g., UDP-glucose and LTD4 [11] and the present
paper), and that, as a result of cell damage and death,
massive release of nucleotides and cysLTs occurs in the
injured area [9] we propose this differential behaviour be
due to the fact that only GPR17+ precursor cells in the
parenchyma have access to and can be activated by their
endogenous ligand under these conditions.
Conclusion
In summary, our study reveals the new cysLT/uracil nucleotide
receptor GPR17 as a ‘‘sensor’’ that is activated upon brain injury in
several embryonically distinct cell types (neurons, microglia and
adult neural precursor cells) that contribute to damage evolution
and to the subsequent remodeling and repair. These findings are
consistent with the emerging role played by endogenous cysLTs and
nucleotides in the injured brain, when these molecules are released
from damaged cells, rapidly diffuse in the extracellular environment
and act as ‘‘danger signals’’ to alert responses to damage and start
repair by ligating specific plasma membrane receptors on target
cells. Our unpublished data demonstrate that GPR17 plays a similar
role in other models of central nervous system neurodegenerative
disease such as spinal cord injury, Alzheimer’s disease and multiple
sclerosis (manuscripts in preparation); thus, GPR17 may represents
a sensor of local injury that is activated upon different kinds of
lesions independently of the cause at the basis of damage. Initial up-
regulation of GPR17 in neurons is followed by a second wave of
receptor induction in microglial/macrophages recruited from distal
parenchymal areas and moving towards the lesioned zone.
Our study also reveals GPR17 as an important player in
oligodendrocyte differentiation. At variance from other oligoden-
drogenic determinants, GPR17 is a membrane receptor that can
be easily and immediately activated at the site of injury by its
endogenous ligands to start remyelination. In addition, pharma-
cological strategies aiming to activate this receptor on pre-
oligodendrocytes via small brain-permeable molecules may also
directly contribute to implement intrinsic repair in post-ischemic
regeneration as well as in demyelinating neurodegenerative
conditions such as multiple sclerosis.
Materials and Methods
Cell culture and transfection
Human astrocytoma cells 1321N1 cells were cultured as
described [15]. For [35S]GTPcS, 106 1321N1 cells were seeded
on 75 cm2 flasks and transfected by the calcium phosphate
precipitation method [15].
Primary mixed neuronal/glial cultures from cerebral cortex were
obtained from E18 Sprague-Dawley rats according to standard
procedures [34]. Pregnant animals were euthanized by cervical
dislocation under CO2 anesthesia, and the fetuses removed and put
into ice-cold Hanks balanced salt solution. After dissection of the
cortices, cells were dissociated and plated on poly-L-lysine-treated
2.4 cm diameter glass coverslips (3.56105 cells/coverslip) in Neuro-
basal (Invitrogen, Gibco) with 2% B27 containing 100 U/ml
penicillin, 100 mg/ml streptomycin, 200 mM glutamine, 10 nM
glutamate. At 3 days in vitro (DIV), half of the culture medium was
replaced with fresh medium without glutamate. Double immunoflu-
orescence experiments were performed between 3 to 10 DIV. At 10
DIV, some cultures were treated for 72 h with the following
pharmacological agents: 100 mM UDP-glucose (Sigma-Aldrich), in
the absence or presence of the P2Y receptor antagonist Cangrelor
(10 mM, a gift of the Medicines Company, Parsippany, NJ, USA) or
100 nM LTD4 (Cayman Europe, Tallinn, Estonia) or the combined
treatment 100 nM LTD4+100 mM UDP-glucose, and then fixed for
immunostaining.
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RNA isolation, RT-PCR and cloning of mouse GPR17
In the case of mouse tissue and 1321N1 cells, total RNA was
extracted using the TRIZOLH Reagent (Invitrogen) according to
the manufacturer’s instructions. Retrotranscription to cDNA and
PCR reactions were carried out as described previously [15]. The
following primers were used to detect the expression of mouse
GPR17: Fw 59-GATGAACGGTCTGGAGGCAGCC-39; Rv 59-
CTCACAGCTCGGATCGGGCAC-39 (PCR product: 1022 bp,
TA: 61.4uC). The same primer pair, external to the open reading
frame, was used to clone mouse GPR17 (NM_001025381) into a
pcDNA3.1 expression vector using the pcDNA3.1/V5-His
TOPOH TA Expression Kit (Invitrogen, Milan, Italy). In the case
of primary mixed neuronal/glial cultures, one living cell, (or a
small group of cells, up to 10), was sucked into a patch pipette by
applying a negative pressure, and then processed for RT-PCR,
using oligo(dT) for retrotrascription (Invitrogen), as previously
described [15]. Choice of oligodendrocyte cells was done at the
light microscope, using cell morphology as a guide (see Figure 4
legend). The following primers were used to detect the expression
of rat GPR17: Fw 59-GCTCTTCGCCTGCTTCTACC-39; Rv
59-GCGGACGGCTTTATTCTTGA-39 (PCR product: 610 bp,
TA: 58.6uC). Twenty ml aliquots of the PCR products were size
separated by electrophoresis on a 1,5% agarose gel.
[35S]GTPcS binding assay
Control and transfected 1321N1 cells were homogenized in
5 mM TRIS-HCl, 2 mM EDTA, pH 7.4 and centrifuged at
48000 g for 15 min at 4uC. The resulting plasma membranes were
suspended in binding buffer and used in [35S]GTPcS binding
assay as previously described [11].
Animals and treatments
Male CD1 mice (Charles River, Calco, Italy) weighing 20–25 g,
after intraperitoneally anesthetized with ketamine (0.1 mg/kg) and
xylazine (0.02 mg/kg), underwent permanent MCAo, as previ-
ously described [35]. Drug treatments were as follows: cangrelor (a
single dose of 1.125 mg/animal in 4 ml of saline, a kind gift from
The Medicines Company, Parsippany, NJ, USA) was administered
intracerebroventricularly (i.c.v.) in the contralateral hemisphere,
20 min after MCAo; anti-sense oligonucleotide 616 and corre-
sponding scrambled oligonucleotide (10 mg/animal, i.c.v., in 4 ml
of saline) were administered twice in the contralateral hemisphere,
20 min and 24 h after MCAo. All i.c.v. administrations were
performed 1 mm lateral to the middle line, 0.45 mm caudal to
bregma, and 2.25 mm depth.
Bromodeoxyuridine (BrdU; 50 mg/kg i.p., Sigma-Aldrich) was
given by a single injection in intact mice to evaluate the
proliferative activity of GPR17+ cells or twice daily for 3 days
from 3 hours after MCAo. The animals were then euthanized 1
day, 2, or 3 days after the last injection. This study on animals has
been approved by the Council of the Department of Pharmaco-
logical Sciences of the University of Milan, Italy, which is legally
entitled for the use of animals for scientific proposes (D.M. of
Italian Ministry of Health, Authorization # 124/2003 of 13/10/
2003 and #143/2004 of 13/12/2004), which is, in turn, based on
the D.L. of 27 January 1992 nr. 116. Implementation of European
Union Directive nr. 86/609/CEE regarding the Protection of
animals used for experimental and other scientific purposes.
MRI analysis of ischemic damage development
Brain infarct size was visualized by MRI measurements taken 2,
24 and 48 h after MCAo using a 4.7 T, vertical super wide bore
magnet of a Burker Avance II spectrometer with micro imaging
accessory. Animals were anesthetized with 1.5% isofluorane in
70% N2 30% O2, fixed on the holder and placed into the 3.8 cm
diameter birdcage coil. A 3-orthogonal-plane, gradient echo scout
acted as a geometric reference for locating the olfactory bulb; then,
caudally, 12 contiguous coronal DW slices were acquired. The
field of view was 2.5661.6 cm2, the in plane resolution was
2006200 mm2 and the slice thickness was 800 mm in all the
images. Spin echo DW images were acquired with 40 ms echo
time and 1.5 s repetition time. Diffusion weighting was obtained
by two 10 ms long and 25 ms spaced gradients resulting in a b
value of about 900 s/mm2. Trace of diffusion tensor map
computation, ischemic volume determination and progression of
the ischemic damage over time were as described [36].
Western Blot analysis
Total protein extracts were obtained by tissue homogenization
in 4 mM HEPES buffer, pH 7.3, containing 250 mM sucrose and
protease inhibitors. The homogenate was centrifuged at 800 g for
10 min at 4uC, and then the supernatant was centrifuged at
200000 g for 1 h at 4uC to generate membrane and cytosolic
fractions. The protein concentration was estimated by the
Bradford procedure (Bio-Rad Laboratories). Equal amounts of
protein from plasma-membranes and cytosolic fractions (30 mg)
were loaded on 10% SDS-PAGE and blotted on nitrocellulose
paper (Invitrogen). Nitrocellulose membranes were then incubated
with rabbit anti-GPR17 polyclonal antibody (1:1000) for 2 h at
RT. Specific signals were detected using the ECL immunoblotting
detection system (Amersham Life Science).
Immunohistochemistry, confocal and fluorescence
microscopy
GPR17 expression pattern was evaluated and confirmed on
paraffin-embedded, frozen and floating brain sections. For paraffin
embedding, the removed brains were fixed in Carnoy reagent,
embedded in Paraplast (Sigma-Aldrich), and 8 mm coronal
sections were processed for immunohistochemistry as previously
described [11]. For frozen and floating sections, the animals have
been perfused with with 4% paraformaldehyde in 0.01 M PBS
and then incubated for 24 hours in a solution of 30% sucrose,
embedded in OCT (Cell Path) and then frozen at 280uC. After
perfusion and brain cryoprotection, 14 mm frozen sections or
30 mm floating sections were cut with a microtome or a vibratome,
respectively, and treated as in [16]. Double labeling of brain
sections was performed using the rabbit anti-GPR17 polyclonal
antibody (1:100) generated as previously described [11] in
combination with the selected primary antibody, in PBS 0.01 M,
0.1% Triton X-100. For co-localization studies, the following
mouse monoclonal antibodies were used: anti-SMI311 (1:300,
Sternberger Monoclonal Inc.), anti-NeuN (1:300, Chemicon), anti-
GFAP (1:600, Cell Signalling), anti-S100b (1:1000, Sigma-
Aldrich), anti-CNPase (1:100, Chemicon), anti-MAG (1:500,
Chemicon), anti-nestin (1:200, Chemicon), anti-HSP70 (1:3000,
Sigma-Aldrich), anti-APC CC-1 clone (1:50, Calbiochem). In
addition, the rat monoclonal anti-myelin basic protein (MBP;
1:200, Chemicon) and anti bromodeoxyuridine (1:150, Abcam)
were used. Double labelings with the rabbit anti-Olig2 (1:800,
Chemicon), anti-NG2 (1:200, Chemicon), doublecortin (DCX;
1:100, Cell Signalling), anti-Iba1 (1:1000, Wako Chemicals, Neuss,
Germany), and with isolectin B4 (IB4) HRP-conjugated (1:100,
Sigma-Aldrich) were also performed. When co-staining with
primary antibodies developed in the same species, GPR17 was
detected with the high sensitivity tyramide signal amplification kit
(Perkin Elmer). Double labeling with anti-NG2 was performed
using detergent free buffers.
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For detection, goat anti-rabbit AlexaFluor 555 (1:500), goat
anti-rat AlexaFluor 555 (1:500), goat anti-mouse AlexaFluor 488
(1:600, all from Molecular Probes) or goat FITC-conjugated anti-
HRP (1:100, Jackson Immunoresearch) were used. In selected
experiments an additional step with the UV fluorescent dye
Hoechst 33258 (1:50000, Molecular Probes) for the nuclei labeling
was performed.
Immunocytochemistry
Immunofluorescence analysis of cortical cultures was performed
as previously described [37]. Double immunostaining was
performed incubating fixed cultures with anti-GPR17 polyclonal
antibody (1:150, 2.5 h at room temperature) [11] and one of the
following primary antibodies: mouse anti-b-Tubulin-III (b-TubIII;
1:100), mouse anti-nestin (1:100), mouse anti-CNPase (1:100), rat
anti-MBP (1:200), mouse anti-O4 (1:100, all from Chemicon),
mouse anti-NG2 (1:200, Abcam), mouse anti-MAP2 (1:500,
Immunological Sciences), and mouse anti-GFAP (1:500, Cell
Signalling). Cells were then incubated for 1 h at RT with the
secondary goat anti-rabbit and goat anti-mouse antibodies,
conjugated to AlexaFluor 488 or AlexaFluor 555 (1:600,
Molecular Probes). Coverslips were mounted with Fluorescent
mounting medium (Dako), and analyzed by using an inverted
fluorescence microscope (200 M; Zeiss) equipped with a CCD
camera (AxioCam HRm; Zeiss), connected to a PC equipped with
the Axiovision software (Zeiss).
Propidium Iodide (PI) staining
To evaluate the viability of in vitro cell cultures, after
pharmacological treatments, cultures were loaded with 20 mM
PI for 10 min. Under these conditions, PI can only enter cells with
damaged permeabilized membrane and cannot label nuclei of
intact viable cells. Cultures were then fixed with 4% paraformal-
dehyde plus 4% sucrose, and loaded with the nuclear dye Hoechst
33258. Nuclei were analyzed and counted using a fluorescence
microscope (Zeiss). Since Hoechst 33258 gives a blue colour to
nuclei under UV light, cells that remained alive during the
pharmacological treatments showed blue nuclei with rounded
appearance; conversely, cells that underwent cell death showed a
red colour due to the incorporation of both dyes and were
classified as dead. Data are presented as percentage of propidium
iodide-positive nuclei over Hoechst 33258-labeled nuclei.
Data analysis
For [35S]GTPcS binding data analysis and graphic presenta-
tion, a non-linear multipurpose curve-fitting program Graph-Pad
Prism was used and the EC50 values were derived. Data are
reported as mean6SEM of three different experiments (performed
in duplicate).
For MRI studies, data on progression of ischemic damage over
time were evaluated by ANOVA for repeated measures. For each
animal, the ischemic area at 2 h after ischemia induction was set to
100%, and the extension of the ischemic area at all other time
points was proportionally calculated, thus providing an internal
control of ischemia development. Then, variations of ischemic
volumes between animals and groups were compared. Six
animals/group were used. Data are expressed as mean values6
s.em. P values #0.05 were considered statistically significant.
Quantifications of immunoreactive cells were performed by
fluorescence microscopy blindly in coronal sections of three intact
and three lesioned hemispheres. Cells were counted using a 206
objective on an inverted fluorescence microscope (200 M; Zeiss).
Depending on the experiment and on the parameters to be
estimated, at least 700 cells/condition were counted.
Ethical declaration
This study on animals has been approved by the Council of the
Department of Pharmacological Sciences of the University of
Milan, Italy, which is legally entitled for the use of animals for
scientific proposes (D.M. of Italian Ministry of Health, Authori-
zation # 124/2003 of 13/10/2003 and #143/2004 of 13/12/
2004), which is, in turn, based on the D.L. of 27 January 1992 nr.
116. Implementation of European Union Directive nr. 86/609/
CEE regarding the Protection of animals used for experimental
and other scientific purposes.
Supporting Information
Figure S1 Endogenous and heterologous expression of murine
GPR17 (A) RT-PCR analysis of GPR17 in various mouse tissues.
Specific transcripts are found in brain and, to a lower extent, in
kidney, heart and skeletal muscle. No detectable expression is
found in liver and lung. Amplification of b-actin is shown as an
internal reaction control. (B) 1321N1 human astrocytoma cells
were heterologously transfected with either pcDNA3.1 empty
vector or pcDNA3.1-Gpr17m, as indicated. RT-PCR analysis
shows the presence of the receptor transcript at the expected
length of 1022 bp in the lane corresponding to the Gpr17
transfected cells. No amplification products are detected in the
absence of retro-transcription (indicated as -) or in cells transfected
with the empty vector. (C) Fluorescence immunocytochemistry in
1321N1 cells shows that no expression of GPR17 can be detected
in cells transfected with pcDNA3.1 empty vector incubated with
the anti-GPR17 antibody (left panel), whereas a specific signal
(green fluorescence) is present in cells transfected with pcDNA3.1-
Gpr17m (center panel). To confirm the specificity of the signal,
preincubation of the antibody with its neutralizing peptide
abolishes GPR17 positivity in these cells (right panel). Scale bar:
30 mm.
Found at: doi:10.1371/journal.pone.0003579.s001 (0.49 MB TIF)
Figure S2 Association of GPR17+ cells with myelinating fibers.
Double staining fluorescence microscopy image of GPR17+
ramified precursor cells (green fluorescence) and MBP+ myelinat-
ing tracts (red fluorescence) in the intact c. striatum. Immature
GPR17+ precursors cells do not co-express MBP but are often
found physically associated to or inside MBP+ myelinating fibers.
These cells may represent a source of pre-oligodendrocytes able to
turn into myelinating cells when necessary; alternatively, they
could play a role in the local trophic control of myelination. Scale
bar: 50 mm.
Found at: doi:10.1371/journal.pone.0003579.s002 (0.54 MB TIF)
Figure S3 Potential Olig2 binding sites upstream of the GPR17
coding sequence. Sequence alignments of 8 Kb upstream to the
coding sequence of the human, rat and mouse GPR17 gene have
been performed using BLAST program from NCBI (http://blast.
ncbi.nlm.nih.gov). Identification of responsive sites for Neurogenin
and NeuroD family of transcription factors (such as Atoh1,
Neurod1, Neurod2, Neurod4, Neurod6, Neurog1, Neurog2,
Neurog3, TGF12 and TGF3 and Olig2) in the upstream
sequences of GPR17 (human, rat and mouse) was performed by
using MatInspector Release Professional 7.7.3 software from
Genomatix. GPR17 upstream sequences globally display a low
homology rate in the three species, except in six regions which are
highly homologous and conserved among phylogenesis. Here we
show only the two of them (E-Box 1 and E-Box 2) in which the E-
Box element, potentially able to bind Olig2, is identical in human,
mouse and rat.
Found at: doi:10.1371/journal.pone.0003579.s003 (0.36 MB TIF)
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